Navigation Links
CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
Date:10/24/2011

n expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the regulatory approval process and related studies can be time consuming and costly, and our ability to market and distribute BioFoam in the desired jurisdictions may be delayed or denied based on the results of these studies.  Studies may also be delayed if we are unable to successfully enroll the requisite number of patients in each respective study in a timely manner.  Based on changing conditions in our Company and in the economy generally, management may decide to terminate its pursuit of regulatory approval for BioFoam at any stage in the approval process, and our current plans and timeline for regulatory approval may be altered.  Also, BioFoam may not provide the anticipated medical benefits, may not ultimately be accepted by physicians and patients, and competing products and solutions may be developed that adversely impact future BioFoam sales.  Our estimates regarding the European and worldwide market for BioFoam may be incorrect and we may not be successful in our attempts to market BioFoam in Europe or in other parts of the world. The potential market for BioFoam could be impacted by a number of factors, including the effectiveness and relative cost of competing products, the impact of future surgical innovations and medical breakthroughs and the perceptions of surgeons and other medical professionals regarding the treatment of liver disease.  For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2010, and the Company's subsequent Form 10-Q filings.  The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site:

ht
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
10. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
11. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  MedScope ( www.medscope.org ), the leading provider of medical ... Connected World magazine Connected World Award for its ... be used anywhere, anytime. The nomination was made by ... nominating MedScope, Landon Garner , Director of Marketing ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... PHILADELPHIA , Jan. 23, 2015  Pete Rose, baseball,s all-time ... joint and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... and we are excited to have him on board with ... . "He is a legendary player who is known across ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4Pete Rose bets on Myoflex to relieve aches and pains 2
... , Pain relieving effects of MoxDuo(TM) IR ... patients with post-operative pain following total knee replacement , ... 26 QRxPharma Limited (ASX: QRX) and (OTCQX: QRXPY) announced ... analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) ...
... , , SAN DIEGO, ... today announced that all patients enrolled in the Company,s MATRIX clinical ... it plans to provide detailed safety and efficacy data in late ... , , The Phase 2b MATRIX clinical trial ...
Cached Medicine Technology:MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 2MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 3MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... 26, 2014 The US represents the largest ... In 2013, GlobalData’s forecast estimates that sales of branded therapies ... due to the high incidence of the disease, high drug ... Japan, and China. Increased sales of CRC therapies over the ...
(Date:12/26/2014)... December 26, 2014 Cooking and warming ... of 5. This score reflects slightly positive negotiation conditions for ... switching costs and a low level of price volatility. “However, ... for cooking and warming equipment and high volatility in the ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... offer a new way to detect and treat autism during ... months of life, when the brain is ... agree that,the earlier autism is diagnosed and therapy begun, the ... even when parents have an intuition,that "something is amiss" with ...
... Low Fat, Rich and Creamy Beverage ... FULLERTON, Calif., March 11 Wildwood Organics, a,division of ... today launched Probiotic Soymilk(TM). This delicious beverage is,certified organic, ... of soy protein per serving. Probiotic Soymilk(TM) is also ...
... a global,leader in dental and aesthetic lasers, today ... tissue lasers will receive a,tuition-free introductory laser certification ... dental laser education. The partnership is,the latest milestone ... education., "We fully recognize that training is ...
... and Phase II Trials, with Some Patients Already Past the Expected Median Average ... Survival Time for This Population -, - Data From Dosimetry Trial ... ... March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
... March 10 As a longtime resident of Southern,Nevada, ... who have been,affected by this situation. I understand that ... against me and the Endoscopy Center of,Southern Nevada. While ... I,am unfortunately unable to do so at this time ...
... N.C., March 10 Cogdell Spencer,Inc. (NYSE: CSA ... 100,percent of the stock of Marshall Erdman and Associates. ... integrated healthcare real estate,company in the country, with over ... on January 23, 2008, was financed,through a $100 million ...
Cached Medicine News:Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:Wildwood Organics Introduces Probiotic Soymilk(TM) 2Health News:HOYA ConBio Partners With Advanced Laser Training to Offer Complementary Laser Certification Course in Dentistry 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 3Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 4Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 5Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 6Health News:Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger 2
Calculate accurate growth percentiles and Z scores using the latest CDC growth charts....
PDA-version of the leading portable drug reference....
PDA application containing all 7,000+ Physicians' Current Procedural Terminology codes developed by the American Medical Association....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Medicine Products: